GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Float Percentage Of Total Shares Outstanding

CASI Pharmaceuticals (FRA:ENM) Float Percentage Of Total Shares Outstanding : 66.01% (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CASI Pharmaceuticals's float shares is 8.84 Mil. CASI Pharmaceuticals's total shares outstanding is 13.40 Mil. CASI Pharmaceuticals's float percentage of total shares outstanding is 66.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CASI Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CASI Pharmaceuticals's Institutional Ownership is 0.23%.

CASI Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CASI Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=8.84/13.40
=66.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ABIO LEXX EQ OCUP KRON ALGS AADI CLNN MLEC INAB OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CASI:USA
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
Website
https://www.casipharmaceuticals.com
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines